Anakinra
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Anakinra: From Rheumatoid Arthritis to Extracutaneous Mastocytoma
One-Sentence Summary
Anakinra is a recombinant human interleukin-1 receptor antagonist (IL-1Ra), used in major markets outside Taiwan for rheumatoid arthritis and several hereditary autoinflammatory diseases. The TxGNN model assigns its highest score to Extracutaneous Mastocytoma (rank 1, score 99.93%), yet no clinical trials or publications have been identified for this specific indication. The evidence level is L5 (model prediction only), and the recommended decision is Hold; notably, stronger mechanistic and clinical evidence exists for other top-10 predicted indications, particularly pyogenic autoinflammatory syndrome (rank 9, L3, Proceed with Guardrails).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid arthritis (not marketed per regulatory records in this evidence pack) |
| Predicted New Indication | Extracutaneous Mastocytoma |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| Market Status | ✗ Not marketed (per regulatory records) |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why Is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack. Based on publicly known information, Anakinra competitively blocks both IL-1α and IL-1β from binding to the IL-1 type I receptor (IL-1RI), thereby suppressing downstream pro-inflammatory signaling — including NF-κB activation, prostaglandin synthesis, and cytokine cascades. This broad blockade of the IL-1 axis underpins its efficacy across a wide spectrum of inflammatory diseases.
Extracutaneous mastocytoma is an extremely rare, benign, localized mast cell tumor arising outside the skin. Mast cells are known secretors of IL-1β, and theoretically IL-1Ra could dampen mast cell–driven local inflammation. However, the dominant pathology of extracutaneous mastocytoma is clonal mast cell proliferation rather than a primary IL-1-mediated inflammatory cascade. The role of IL-1 as a disease driver in this entity has not been established, making the mechanistic connection indirect and speculative.
Context across the full top-10 prediction list is important: stronger mechanistic links and actual clinical evidence exist further down the ranked list. Pyogenic autoinflammatory syndrome (PAPA/PAPASH, rank 9) is directly driven by PSTPIP1 mutations that hyper-activate the IL-1β inflammasome — a textbook target for anakinra — and is supported by a systematic review plus multiple case series (L3 evidence, Proceed with Guardrails). Autosomal recessive familial Mediterranean fever (rank 3) is similarly an IL-1-pathway–driven monogenic disease with strong mechanistic rationale. The top-ranked prediction’s high TxGNN score likely reflects graph-level topological proximity rather than established clinical relevance for extracutaneous mastocytoma specifically.
Clinical Trial Evidence
Currently no related clinical trials registered for Anakinra in Extracutaneous Mastocytoma.
Literature Evidence
Currently no related literature available for Anakinra in Extracutaneous Mastocytoma.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a near-perfect TxGNN prediction score (99.93%), extracutaneous mastocytoma is an extremely rare benign tumor with no clinical trials, no supporting publications, and no established IL-1 pathway involvement — making this a model-only prediction with insufficient biological or clinical grounding to advance.
To proceed, the following is needed:
- Preclinical data (in vitro or animal models) establishing IL-1β’s causal role in extracutaneous mastocytoma
- Complete mechanism of action documentation retrieved from DrugBank API or official package insert
- Safety profile (key warnings, contraindications) extracted from the regulatory package insert to enable S1 safety screening
- Evaluation of whether repurposing resources would be better directed toward higher-evidence indications already in the top-10 list, specifically:
- Pyogenic autoinflammatory syndrome (rank 9, L3, Systematic Review available — Proceed with Guardrails)
- Autosomal recessive familial Mediterranean fever (rank 3, strong mechanistic link; likely a data collection gap rather than true absence of evidence)
- Aggressive systemic mastocytosis (rank 4, L4, case-level literature on IL-1 inhibition in related mast cell–activation conditions)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.